Riot Games released a new Dev Update covering League of Legends gameplay balance, more ranked changes, and details on First ...

Microsoft has released ASP.NET Core in .NET 11 Preview 1, introducing new Blazor components like EnvironmentBoundary, Label, and DisplayName, along with relative URI navigation, QuickGrid row click ...

Exposure to the product "may cause temporary or medically reversible adverse health consequences," according to the FDA.

The in-development feature reported by @nima_owji shows a toggle that allows users to disclose synthetically made or ...

Timi is a news and deals writer who's been reporting on technology for over a decade. He loves breaking down complex subjects into easy-to-read pieces that keep you informed. But his recent passion ...

Immigration officials are testifying before the House Homeland Security Committee on Tuesday for the first time since two U.S. citizens were killed in the recent immigration crackdown in Minneapolis.

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...

Google Warns Over 1 Billion Android Phones Are Now at Risk Your email has been sent If you’re using an older Android phone, Google has a message you probably don’t want to hear. More than 40% of ...

The FDA has updated the safety labeling for axicabtagene ciloleucel (Yescarta, Kite Oncology) ­— a CAR T-cell therapy — extending its indication to include patients with relapsed or refractory primary ...

FDA lifts Yescarta limits for relapsed primary CNS lymphoma, expanding CAR T access with phase 1 safety data—what to know about neuro risks. The FDA has approved a label update for axicabtagene ...

– Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified – Primary central nervous system lymphoma is ...